Idiopathic thrombocytopenic purpura (ITP) is a relatively common disease, with an incidence of 2.25-6.6/100,000/year.\(^1\) Until recently, the main pathology of ITP was thought to be due to autoantibodies attached to the platelets causing their destruction by reticuloendothelial systems, particularly the spleen; however, defective thrombopoiesis and T-cell mediated platelets destruction have been discovered.\(^4\) The natural history of ITP is scantily defined, but some studies showed that they had a good outcome and mortality equal to the general population while having more morbidity from the treatment rather than the disease.\(^7\)\(^-\)\(^12\) Bleeding is usually uncommon in ITP except in severe cases (platelets count<30x10^9/l) and clinical presentation varies from asymptomatic, mild bleeding or serious bleed like intracranial hemorrhage. Patients with platelet counts >50x10^9/l need no treatment except if they are undergoing procedures expected to induce blood loss. Steroids and immunoglobulins are considered as first-line therapy, although there are no randomized trials addressing their use versus no treatment.\(^7\)\(^-\)\(^13\) Splenectomy is reserved for those who fail steroid therapy. Few randomized trials comparing the conventional-dose of prednisolone (1 mg/kg/day) versus the low-dose (0.25-0.5 mg/kg/day) showed no significant difference.\(^1\)\(^,\)\(^3\)\(^,\)\(^8\)\(^,\)\(^12\)\(^,\)\(^14\)\(^-\)\(^17\) Although, prednisolone in the conventional-dose is still recommended as the initial therapy.\(^2\)

The aim of this study is to assess the efficacy of low-dose prednisolone (0.25 mg/kg/day) compared to conventional-dose (1 mg/kg/day) in patients with ITP.

**METHOD**

Patients diagnosed with ITP from January 2003 to December 2005 were recruited in the treatment protocol. ITP was diagnosed according to the accepted criteria: isolated thrombocytopenia with platelets count below 150x10^9/l, normal hemoglobin level, white blood cell counts, differentials, and peripheral blood smear. In addition, history and physical examinations were not suggestive of any other diseases. Bone marrow examination was not routinely performed. Written informed consent was obtained from each patient. The study was approved by the local ethical committee.

---

* Assistant Professor
** Assistant Professor
Arabian Gulf University
Salmaniya Medical Complex
Kingdom of Bahrain
Email: kamsharif@gmail.com
Patients were treated with 1 gm IV methylprednisolone once daily for three days. On day 4, patients were randomized to either group I who received low-dose prednisolone (0.25 mg/kg/day) or group II who the conventional therapy 1 mg/kg/day. Both treatment modalities were continued for four weeks and then gradually tapered to be discontinued over the fifth week. Patients with serious bleeding (CNS or GIT) could receive intravenous immunoglobulin irrespective of randomization (1-2 gm/kg total dose over 1-5 days); however, none of the patients had severe bleeding that warranted this intervention. Figure 1 shows a summary of the flow of participants through each stage of randomization.

**Figure 1: Randomization of Low-Dose and High-Dose of Prednisolone in Idiopathic Thrombocytopenic Purpura**

Patients with platelet count more than 50x10^9/L, patients with secondary ITP including drug-induced ITP or patients who received steroid therapy before admission were excluded. However, the virus associated ITP such as HIV, hepatitis B and C and EBV were included.

Follow-up was arranged for all patients monthly for the first year, quarterly for the second year, then once every six months for the third year and then annually. The mean follow-up for all patients was 11 months, 5-24 months. None was lost to follow-up. Patients were assessed clinically and complete blood count (CBC) was performed.

Complete remission (CR) was defined as platelet counts of ≥150x10^9/L, while partial remission (PR) was considered when platelet counts are ≥50x10^9/L but <150x10^9/L. Death or failure to achieve CR/PR after two months of treatment or reduction of platelet counts during tapering down the prednisolone dose were considered treatment failures.

Although, relapse is described as platelet counts <150x10^9/L if previously in CR, or <50x10^9/L if previously in PR.

Data were analyzed using SPSS 17. The results were analyzed using Mann-Whitney to test differences between means of quantitative variables and Chi-Square to test the differences between proportions of qualitative variables.

**RESULT**

Forty-one patients were included in the study from January 2003 to December 2005; 29 (70.7%) were females, of which one was diagnosed in the postpartum period, and 12 (29.3%) were males. Twenty-one (51.2%) patients were randomized to low-dose prednisolone (group I) and 20 (48.78%) received the conventional-dose (group II). The mean age for group I was 29 years (range 14-47 years); the mean age for group II was 39 years (range 20-90 years). Clinically, all patients presented with thrombocytopenia with a mean platelet count of 11x10^9/L and 8.7x10^9/L. None of the patients presented with bleeding. Both groups were matched and homogenous in personal characteristics and clinical features, see table 1.

**Table 1: Personal Characteristics and Clinical Features**

<table>
<thead>
<tr>
<th>Age range</th>
<th>Group I</th>
<th>Group II</th>
<th>Total</th>
<th>P-Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>(Mean±SD)</td>
<td>14-47</td>
<td>20-90</td>
<td>14-90</td>
<td>0.066*</td>
</tr>
<tr>
<td>Pregnancy</td>
<td>1 (4.76%)</td>
<td>0 (0%)</td>
<td>21 (51.2)</td>
<td>0.920a</td>
</tr>
<tr>
<td>Mean Platelets count on Admission</td>
<td>11.14±13.73</td>
<td>8.7±7.65</td>
<td>9.95±11.12</td>
<td>0.854*</td>
</tr>
</tbody>
</table>

The OR for both groups was 78.05%. There was no statistically significant difference between both groups in terms of group specific OR (81% versus 75%, P=0.645), group specific CR (52.4% versus 50%, P=0.879) or PR (28.6% versus 25%, P=0.92). None died, although 8 (19.5%) patients failed to achieve remission, four patients in each group; five (12.2%) of them subsequently had splenectomy and achieved complete remission, while the remaining responded to the second course of steroid. Nevertheless, the difference was not statistically significant comparing the two regimens.

Fourteen (34.15%) patients relapsed following a mean response period of 11.14±13.73 months; 6 (28.6%) in group I and 8 (40%) in group II. Once again, the difference was not statistically significant, P=0.92. Overall, 13 (31.7%) patients had splenectomy to maintain adequate platelet counts 6 (28.6%) in group I and 7 (35%) in group II. There was no statistical difference between both groups whether we consider splenectomy rate following treatment failure or consequent to relapse.

Two patients developed complications related to steroids therapy. One developed ischiorectal abscess and the other one developed hyperglycemia and glaucoma, both were in group II, and none of group I developed any complications related to steroid; still, these were statistically not significant, see table 2.

**Table 2: Patients Outcome**

<table>
<thead>
<tr>
<th>Outcomes</th>
<th>Patients</th>
<th>Group I</th>
<th>Group II</th>
<th>P-Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Complete remission (CR)</td>
<td>21 (51.2)</td>
<td>11 (52.4%)</td>
<td>10 (50%)</td>
<td>0.879*</td>
</tr>
<tr>
<td>Partial remission (PR)</td>
<td>11 (26.8%)</td>
<td>6 (28.6%)</td>
<td>5 (25%)</td>
<td>0.920*</td>
</tr>
<tr>
<td>Overall remission (OR)</td>
<td>32 (78%)</td>
<td>17 (81%)</td>
<td>15 (75%)</td>
<td>0.645*</td>
</tr>
<tr>
<td>Failure</td>
<td>8 (19.5%)</td>
<td>4 (19%)</td>
<td>4 (20%)</td>
<td>0.627*</td>
</tr>
<tr>
<td>Death</td>
<td>0 (0%)</td>
<td>0 (0%)</td>
<td>0 (0%)</td>
<td>NA*</td>
</tr>
<tr>
<td>Relapse rate (RR)</td>
<td>14 (34.15%)</td>
<td>6 (28.6%)</td>
<td>8 (40%)</td>
<td>0.438*</td>
</tr>
<tr>
<td>Infection</td>
<td>0 (0%)</td>
<td>1 (5%)</td>
<td>NA*</td>
<td></td>
</tr>
<tr>
<td>Complications</td>
<td>0 (0%)</td>
<td>1 (5%)</td>
<td>NA*</td>
<td></td>
</tr>
<tr>
<td>Splenectomy</td>
<td>13 (31.7%)</td>
<td>6 (28.6%)</td>
<td>7 (35%)</td>
<td>0.658*</td>
</tr>
</tbody>
</table>

*not significant
bnot applicable
DISCUSSION

ITP is an autoimmune disease which is benign in nature; less than 5% run a severe chronic course which dictates a difficult management approach1-3.

Prednisolone at a dose of 1 mg/kg/day is used as initial therapy for ITP by many experts since the recommendations by Dameshek et al in 1958,16-20. However, the role of prednisolone at this dose, the duration of the therapy, rate and sustainability of the remission is not clear2,3,5,9,10,16,17. In addition, the role of steroid in the natural course of the disease is also doubtful7,8,10,13.

Moreover, several studies addressed and compared the conventional-dose of steroid versus low-dose (between 0.25-0.5 mg/kg/day) and showed no significant difference between the regimens3,8,12,14-17.

Bellucci et al found no significant difference in response rate or rapidity of response in adults with acute ITP to low-dose of prednisolone (0.25 mg/kg/day) versus conventional-dose (1 mg/kg/day)9. Similarly, Mazzucconi et al reported no significant difference in remission rate between high-dose prednisolone (1.5 mg/kg/day) and low-dose prednisolone (0.5 mg/kg/day)10.

Several studies compared conventional and low-dose of prednisolone reported no significant difference in remission rate; however, these were in non-English language and only abstract were available in English15,16.

We found no statistically significant difference in the rate of remission between the two groups, whether considering overall remission (OR), complete remission (CR) or partial remission (PR), which was similar to the finding in the study by Bellucci et al and others3,8,12,14-17.

Our study recommends the use of low-dose because it is not resulting in more failures. Furthermore, those failures responded to a second course of the same dose of prednisolone or Splenectomy without any significant complications.

Fourteen patients (34.15%) had relapsed during a mean follow-up period of eleven months; this is comparable to other reported studies, although there were six relapses in group I and eight in group II; however, these were not statistically significant7-12.

Two patients in group II developed complications related to steroid therapy, one had an ischiorectal abscess and the other patient developed hyperglycemia and glaucoma while none of group I developed any complications. This was not statistically significant because of the small number of patients; however, it shows that high-dose is associated with more complications22.

The rate of Splenectomy was comparable in both groups indicating that low-dose prednisolone did not increase the need for Splenectomy.

CONCLUSION

This study, though it has a small number of patients, showed that low-dose of prednisolone (0.25mg/kg/day) is as effective as the conventional-dose (1mg/kg/day).

The high-dose prednisolone is more expensive and is associated with more complications compared with low-dose and eventually, it would reduce the burden on health services.

Therefore, we recommend the use of low-dose prednisolone as initial therapy for ITP rather than the high-dose.

Author Contribution: All authors share equal effort contribution towards (1) substantial contribution to conception and design, acquisition, analysis and interpretation of data; (2) drafting the article and revising it critically for important intellectual content; and (3) final approval of manuscript version to be published. Yes.

Potential Conflicts of Interest: None.

Competing Interest: None. Sponsorship: None.

Submission Date: 7 April 2015. Acceptance Date: 13 October 2015.

Ethical Approval: Approved by the Ethical Committee, Salmaniya Medical Complex, Kingdom of Bahrain.

REFERENCES